Time to recurrence and patient survival in recurrent oral squamous cell carcinoma.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
07 2019
Historique:
received: 13 03 2019
revised: 28 04 2019
accepted: 05 05 2019
entrez: 11 6 2019
pubmed: 11 6 2019
medline: 23 5 2020
Statut: ppublish

Résumé

Tumour relapse remains one of the major problems in managing oral squamous cell carcinoma (OSCC) with mortality rates of up to 92%. Early recurrences have a worse prognosis than late relapses. However, few has been written about the influence of clinicopathological parameters on the timing of recurrence and the patient survival. Retrospective chart review of 159 patients with an OSCC recurrent disease. Exclusion criteria were neoadjuvant chemoradiotherapy, follow-up <6 weeks, perioperative death, second primaries and inadequate information on clinicopathological parameters. Statistical analysis was performed using univariate and multivariate analysis. A significant correlation was found in the χ2-analysis between the timing of recurrence and the margin status (p = 0.020), lymph node ratio (p = 0.030) and grading (p = 0.003) of the primary tumour. In the multivariate survival analysis, the timing of recurrence (p < 0.001), margin status of the primary tumour (p = 0.023), presence of extracapsular spread in the primary tumour (p = 0.003) and performance of a salvage treatment (p < 0.001) were shown to be independent risk factors for overall survival. For patients with a recurrent OSCC, the time to recurrence, margin status, extracapsular spread and the performance of a salvage treatment are independent prognostic factors for overall survival. Furthermore, a significant association exists between the moment of recurrence and the lymph node ratio, the margin status and grading of the primary tumour. This knowledge can allow for the development of individualised surveillance programs and like this, an earlier diagnosis and better second treatment chance in the case of a recurrence.

Identifiants

pubmed: 31178216
pii: S1368-8375(19)30140-X
doi: 10.1016/j.oraloncology.2019.05.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8-13

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Annelies Weckx (A)

Department for Oral and Craniomaxillofacial Plastic Surgery, University of Cologne, Kerpenerstraβe 62, 50937 Cologne, Germany. Electronic address: annelies_weckx@hotmail.com.

Maximilian Riekert (M)

Department for Oral and Craniomaxillofacial Plastic Surgery, University of Cologne, Kerpenerstraβe 62, 50937 Cologne, Germany.

Andrea Grandoch (A)

Department for Oral and Craniomaxillofacial Plastic Surgery, University of Cologne, Kerpenerstraβe 62, 50937 Cologne, Germany.

Volker Schick (V)

Department for Anesthesiology and Intensive Care, University of Cologne, Kerpenerstraβe 62, 50937 Cologne, Germany.

Joachim E Zöller (JE)

Department for Oral and Craniomaxillofacial Plastic Surgery, University of Cologne, Kerpenerstraβe 62, 50937 Cologne, Germany.

Matthias Kreppel (M)

Department for Oral and Craniomaxillofacial Plastic Surgery, University of Cologne, Kerpenerstraβe 62, 50937 Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH